Testimonials From The Health Technology Assessment Course
This course is structured, interactive and helpful! The 3 most valuable aspects are: the core perspectives of HTA, the impact on regulatory decisions and the future developments.
MerckGeorgios Amexis, Director Global Regulatory Lead, RAC - Germany - May 2017
Great overview of HTA with a very enthusiastic speaker.
AstraZenecaPieter Van Bochaute, Medical Science Liaison - Belgium - December 2016
Quite a broad subject that was well-explained. By attending this course, you will understand the most recent trends and get interesting examples.
UCBSolène Thieffry, Senior Health Outcomes Manager - Belgium - December 2016
A great overview of the HTA landscape and challenges/opportunities presented in a perfect mix of theory and practical examples – and everything in just one day!
Johnson & JohnsonAndreas Preising, Director Government Affairs & Policy EMEA - Belgium - June 2016
This 1-day HTA course with Prof Lieven Annemans was extremely useful as I learnt about joint initiatives, how to get into dialogue in an early phase, harmonization, the criteria, do’s & don’ts etc. Highly recommendable!
Siemens HealthcareDr. Bernhard Fahn, Head of Health Economics & Outcome Research, Medical Office - Germany - June 2016
Very well-organised HTA course with great content from one of the brightest industry experts!
WellmeraDr. Rosemary Jose, Senior Consultant - Switzerland - June 2016
All the information in this C.E.L.forpharma 1-day HTA course was relevant for my role. I particularly liked the example-based learning approach and would have loved a 2nd day to dive deeper.
JanssenIrina Vasiliu, Market Access Specialist - Romania - June 2016
Great training and content on HTAs, very well adapted to the audience with concrete examples and relevant tips and tricks.
TevaNathalie Plasman, Therapeutic Area Manager - Belgium - June 2016
The course was extremely well organised and had the appropriate expert. Thank you!
UCBMata Charokopou, Senior Manager Health Economics, Global Payer Evidence - Belgium - December 2015
An extremely valuable course for beginners to HTA!
European Generic Medicines AssociationDeniz Kocas, Economics Advisor - Belgium - October 2015
I am extremely happy that I could attend this course - Prof. Annemans made a complicated subject very accessible.
IntermedGülce Belgin, Owner/General Manager - Turkey - October 2015
I value this course a lot as it gave me that missing piece of understanding I was looking for. Prof. Annemans has prepared a truly comprehensive overview of HTA, at the end of which one clearly understands the basic principles behind the assessment, how the process currently works and how it ideally should work. I recommend this course to everyone looking for that missing piece!
Bristol-Myers SquibbLeila Zajac, Regulatory Manager Distributor Markets Europe - Austria - October 2015
An excellent overview! Well worth the trip and a day away from the office. I will return to the office better able to discuss and probe HTA-related issues and opportunities with colleagues and health policy stakeholders.
NovartisJohn-Kenneth Billingsley, Senior Director European Government Affairs - Switzerland - June 2015
This was a very interesting course! As I just started working as a medical project manager in the pharmaceutical industry, I learned a lot!
GileadKim Vanstraelen, Medical Project Manager - Belgium - June 2015
I find this training very useful and fitting to the current needs. Nowadays when developing a program, not only a close interaction with the regulatory agencies is critical but a timely collaboration with HTA stakeholders is required as well.
BayerMonica Bratti, Global Regulatory Strategist - Germany - June 2015
This course gave me an opportunity to take a look into HTA from a broader perspective. I would recommend this course to health authorities. Thank you very much!
Institute of HygieneRaimonda Janoniene, Research and Technology Assessment Manager - Lithuania - June 2015
The best, clearest and most easy to understand explanation of HTA I've ever heard, really! The slides are really good (even pictures are chosen perfectly)!
NovartisAdelina Afzalova, Health Economics and Outcomes Research Manager - Russia - March 2015
This very helpful Health Technology Assessment course will support me a lot in my daily work!
BaxterClaudia Lentner-Böhm, Head of Health Economics Hospital Care DACH - Germany - March 2015
Lieven Annemans is an excellent speaker with the ability to provide an excellent 'helicopter view' of a very complex landscape.
UCB PharmaMarcel Brink, Director Regulatory Affairs - Belgium - March 2015
In one day Lieven Annemans demystifies HTA.
AstraZenecaToke Skovlund, Director Government Affairs & Global Brands - United Kingdom - March 2015
Lieven is an excellent speaker who kept the group engaged throughout the day. I particularly appreciated his ability to relate to pharma executives' real-life experiences.
ShireOswald Bentinck, Global Market Access Director - Switzerland - November 2014
Very efficient learning and a healthy mix of depth and breadth. Congratulations for a successful first HTA training!
NovartisStefan Weber, Director, Payment Policy - Switzerland - November 2014
The Dos and Don'ts in Health Technology Assessments is an excellent program. Prof. Annemans delivers a very practical single day overview encompassing where companies typically fall short and which areas are essential to optimise chances of a successful outcome. I highly recommend this interactive course both to those working in the area and those simply looking to enhance their knowledge of HTA.
Biogen Idec InternationalTim McCormick, VP Business Operations - Switzerland - November 2014
Very clear and well presented! As evidenced by his responses to questions, Lieven has a lot of expertise in this matter. He offered great examples in his HTA course.